Commentary on Kaneko et al.: Intensified chemotherapy increases the survival rates in patients with stage 4 neuroblastoma with MYCN amplification

Journal of Pediatric Hematology/Oncology

Volumn 24, Issue 8, 2002, Pages 608-609

  Brodeur, Garrett M ^a  

^a CHILDREN S HOSPITAL OF PHILADELPHIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; MYC PROTEIN;

CANCER STAGING; CANCER SURVIVAL; CHILD; CONFERENCE PAPER; GENE AMPLIFICATION; GENE EXPRESSION; HIGH RISK POPULATION; HUMAN; NEUROBLASTOMA; ONCOGENE C MYB; OUTCOMES RESEARCH; PRIORITY JOURNAL; PROGNOSIS; RISK ASSESSMENT; RISK FACTOR; STEM CELL TRANSPLANTATION; SURVIVAL RATE;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHILD, PRESCHOOL; DISEASE-FREE SURVIVAL; GENE AMPLIFICATION; GENES, MYC; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; INFANT; NEUROBLASTOMA; PROGNOSIS; SURVIVAL RATE; TRANSPLANTATION CONDITIONING; TREATMENT OUTCOME;

EID: 0036843522     PISSN: 10774114     EISSN: None     Source Type: Journal    
DOI: 10.1097/00043426-200211000-00002     Document Type: Conference Paper

References (23)

1. Brodeur GM, Seeger RC, Schwab M, et al. Amplification of N-myc in untreated human neuroblastomas correlates with advanced disease stage. Science 1984;224:1121-4.
2. Seeger RC, Brodeur GM, Sather H, et al. Association of multiple copies of the N-myc oncogene with rapid progression of neuroblastomas. N Engl J Med 1985;313:1111-6.
3. Alvarado CS, London WB, Look AT, et al. Natural history and biology of stage A neuroblastoma: A Pediatric Oncology Group Study. J Pediatr Hematol Oncol 2000;22:197-205.
4. Bowman LC, Castleberry RP, Cantor A, et al. Genetic staging of unresectable or metastatic neuroblastoma in infants: A Pediatric Oncology Group study. J Natl Cancer Inst 1997;89:373-80.
5. Schmidt ML, Lukens JN, Seeger RC, et al. Biologic factors determine prognosis in infants with stage IV neuroblastoma: A prospective Children's Cancer Group study. J Clin Oncol 2000;18:1260-8.
6. DuBois SG, Kalika Y, Lukens JN, et al. Metastatic sites in stage IV and IVS neuroblastoma correlate with age, tumor biology, and survival. J Pediatr Hematol Oncol 1999;21:181-9.
7. Katzenstein HM, Bowman LC, Brodeur GM, et al. Prognostic significance of age, MYCN oncogene amplification, tumor cell ploidy, and histology in 110 infants with stage D(S) neuroblastoma: The Pediatric Oncology Group experience: A Pediatric Oncology Group study. J Clin Oncol 1998;16:2007-17.
8. Look AT, Hayes FA, Shuster JJ, et al. Clinical relevance of tumor cell ploidy and N-myc gene amplification in childhood neuroblastoma: A Pediatric Oncology Group study. J Clin Oncol 1991;9:581-91.
9. Nickerson HJ, Matthay KK, Seeger RC, et al. Favorable biology and outcome of stage IV-S neuroblastoma with supportive care or minimal therapy: A Children's Cancer Group study. J Clin Oncol 2000;18:477-86.
10. Matthay KK, Perez C, Seeger RC, et al. Successful treatment of stage III neuroblastoma based on prospective biologic staging: A Children's Cancer Group study. J Clin Oncol 1998;16:1256-64.
11. Kaneko M, Tsuchida Y, Mugishima H, et al. Intensified chemotherapy increases the survival rate in patients with Stage 4 neuroblastoma with MYCN amplification. J Pediatr Hematol Oncol 2002;24:xxx.
12. Suita S, Zaizen Y, Kaneko M, et al. What is the benefit of aggressive chemotherapy for advanced neuroblastoma with N-myc amplification? A report from the Japanese Study Group for the Treatment of Advanced Neuroblastoma. J Pediatr Surg 1994;29:746-50.
13. Matthay KK, Villablanca JG, Seeger RC, et al. Treatment of high-risk neuroblastoma with intensive chemotherapy, radiotherapy, autologous bone marrow transplantation, and 13-cis-retinoic acid. Children's Cancer Group. N Engl J Med 1999;341:1165-73.
14. Hartmann O, Valteau-Couanet D, Vassal G, et al. Prognostic factors in metastatic neuroblastoma in patients over 1 year of age treated with high-dose chemotherapy and stem cell transplantation: A multivariate analysis in 218 patients treated in a single institution. Bone Marrow Transplant 1999;23:789-95.
15. Valteau-Couanet D, Benhamou E, Vassal G, et al. Consolidation with a busulfan-containing regimen followed by stem cell transplantation in infants with poor prognosis stage 4 neuroblastoma. Bone Marrow Transplant 2000;25:937-42.
16. Evans AE. D'Angio GJ, Randolph J. A proposed staging for children with neuroblastoma. Children's Cancer Study group A. Cancer 1971;27:374-8.
17. Breslow N, McCann B. Statistical estimation of prognosis for children with neuroblastoma. Cancer Res 1971;31:2098-103.
18. Maris JM, Matthay KK. Molecular biology of neuroblastoma. J Clin Oncol 1999;17:2264-79.
19. Gray JW, Collins C. Genome changes and gene expression in human solid tumors. Carcinogenesis 2000;21:443-52.
20. Kashiwagi H, Uchida K. Genome-wide profiling of gene amplification and deletion in cancer. Hum Cell 2000;13:135-41.
21. Alizadeh AA, Ross DT, Perou CM, et al. Towards a novel classification of human malignancies based on gene expression patterns. J Pathol 2001;195:41-52.
22. Clarke PA, te Poele R, Wooster R, et al. Gene expression microarray analysis in cancer biology, pharmacology, and drug development: Progress and potential. Biochem Pharmacol 2001;62:1311-336.
23. Khan J, Wei JS, Ringner M, et al. Classification and diagnostic prediction of cancers using gene expression profiling and artificial neural networks. Nat Med 2001;7:673-9.